Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01610063 · ClinicalTrials.gov registry record · NA
Evaluation of an Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting
A NA study, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 227
- Enrollment target
NCT01610063: Completed NA study, sponsored by Mayo Clinic.
NCT01610063 is a NA study that has completed, run by Mayo Clinic. The registered enrollment target is 227 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01610063, a NA study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 227 participants
- Enrollment target
Study Summary
This was a study of a genotyping tool that reported on how subjects responded to medications and could be used in a community psychiatry practice to improve medication choice for depression. After the DNA test, an interpretive report was provided to the subjects' physicians. The hypothesis of this pilot study was that it was feasible to use this pharmacogenomic algorithm in a new setting to treat depressed subjects..
Interventions
- OTHER Pharmacogenomic algorithm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 227 participants |
| Start Date | 2009-01 |
| Est. Completion | 2013-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01610063
The ClinicalTrials.gov registry entry for NCT01610063 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pharmacogenomic algorithm is the first listed.
NCT01610063 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01610063 about?
NCT01610063 is a clinical study titled "Evaluation of an Antidepressant Pharmacogenomic Algorithm in an Outpatient Clinical Setting". This was a study of a genotyping tool that reported on how subjects responded to medications and could be used in a community psychiatry practice to improve medication choice for depression. After the DNA test, an interpretive report was provided to the subjects' physicians. The hypothesis of this p...
What is the current status of trial NCT01610063?
This trial is currently completed. It is a NA study. The enrollment target is 227 participants. The study started on 2009-01. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01610063?
The interventions under investigation include: Pharmacogenomic algorithm (OTHER).
Who is sponsoring clinical trial NCT01610063?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.